<SEC-DOCUMENT>0001144204-16-128967.txt : 20161021
<SEC-HEADER>0001144204-16-128967.hdr.sgml : 20161021
<ACCEPTANCE-DATETIME>20161021161322
ACCESSION NUMBER:		0001144204-16-128967
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20161020
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20161021
DATE AS OF CHANGE:		20161021

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		161946418

	BUSINESS ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219
		BUSINESS PHONE:		2149055100

	MAIL ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v450962_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT PURSUANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO SECTION 13 OR 15(D) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
<B>October 20, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>ABEONA THERAPEUTICS INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 34%; text-decoration: underline; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>Delaware</u></b></font></td>
    <td style="width: 33%; text-decoration: underline; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>0-9314</u></b></font></td>
    <td style="width: 33%; text-decoration: underline; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>83-0221517</u></b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of<BR>
 incorporation)</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</font></td>
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer Identification<BR>
 No.)</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3333 Lee Parkway, Suite 600</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Dallas, TX 75219</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>(214) 214-665-9495</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>N/A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see<I>&nbsp;</I>General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>Item 8.01.&nbsp;&nbsp;Other Events
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 20, 2016, Abeona Therapeutics
Inc. issued a press release entitled &ldquo;Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial
at Orphan Drugs &amp; Rare Disease Conference, London UK&rdquo;. The full text of the press release is furnished as Exhibit 99.1
to this Current Report on Form 8-K and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Financial Statements
and</B> <B>Exhibits. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="width: 9%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Exhibit </b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>No.</b></P></td>
    <TD NOWRAP STYLE="width: 1%">&nbsp;</td>
    <TD NOWRAP STYLE="width: 90%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Description</b></P></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</font></td>
    <td>&nbsp;</td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release dated October 20, 2016, entitled &ldquo;Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at Orphan Drugs &amp; Rare Disease Conference, London UK&rdquo;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>





<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td colspan="2" style="text-decoration: underline"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Abeona Therapeutics Inc.</u></font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</td>
    <TD STYLE="width: 5%">&nbsp;</td>
    <TD STYLE="width: 45%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD STYLE="border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <TD STYLE="border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Stephen B. Thompson</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen B. Thompson</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President Finance</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Accounting Officer</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: October 21, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Exhibit Number</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 4%; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</font></td>
    <td style="vertical-align: bottom; width: 1%; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt">&nbsp;</td>
    <td style="vertical-align: top; width: 95%; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release dated October 20, 2016, entitled &ldquo;Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at Orphan Drugs &amp; Rare Disease Conference, London UK&rdquo;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v450962_ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="pg1img1_ex99-1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>Abeona
Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at</B></FONT><FONT STYLE="font-size: 10pt; background-color: white">
</FONT><FONT STYLE="font-size: 18pt"><B>Orphan Drugs &amp; Rare Disease Conference, London UK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>New York, NY, and Cleveland, OH</B> &ndash; <B>October 20,</B>
<B>2016 - </B>Abeona Therapeutics Inc. (Nasdaq: ABEO):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>ABO-102 gene therapy well-tolerated
at low-dose Cohort of 3 subjects </I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Significant average GAG (heparan sulfate)
reduction in urine (</I>57.6% +/- 8.2%) <I>and cerebral spinal fluid (</I>25.6% +/- 0.8%) <I>and reduction in liver (</I>17.1%
+/- 1.9%) <I>and spleen volume </I>(17.6% +/- 7.1%) <I>observed at 30 Days post-intravenous injection</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Company to host investor call at 4:30
EDT today </I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Abeona Therapeutics Inc. (Nasdaq: ABEO),
a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases,<FONT STYLE="background-color: white">
provided today at the Orphan Drugs &amp; Rare Disease Conference (London, UK), an update on clinical results through 30 days post-injection
for the completed low-dose cohort (n=3) </FONT>in the ongoing Phase 1/2 trial for ABO-102 (AAV-SGSH). The first-in-man clinical
trial utilizes a single intravenous injection of AAV gene therapy for subjects with MPS IIIA (Sanfilippo syndrome type A), a rare
autosomal recessive disease affecting every cell and organ in the body causing neurocognitive decline, speech loss, loss of mobility,
and premature death in children.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ongoing Phase 1/2 study is designed
to evaluate safety and preliminary indications of efficacy of ABO-102 in subjects suffering from MPS IIIA. Observations 30 days
post-injection for the low dose cohort demonstrated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">ABO-102 is well-tolerated in subjects
injected with the low dose of 5E13 vp/kg ABO-102 with no treatment related adverse events or serious adverse events (SAEs). Following
favorable review of the safety data by the independent Data Safety Monitoring Board (DSMB), enrollment in the high dose cohort
has commenced.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In the natural history study evaluating
MPS III subjects it was shown that urine and cerebral spinal fluid GAG (heparan sulfate or &ldquo;HS&rdquo;) are significantly
elevated in the subject population as a symptom of disease pathology. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All subjects in the low-dose cohort experienced
reductions from baseline in both urinary HS and CSF. At 30 days post-injection, urinary HS reduction was 57.6% +/- 8.2%. Reduction
in CSF HS was 25.6% +/- 0.8%, suggesting that ABO-102 crossed the blood brain barrier after intravenous administration.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The natural history study in 25 subjects
with MPS III (<I>Truxal et. al., 2016, Mol. Genet. Metab</I>.) demonstrated that subjects had increased liver and spleen volumes
averaging 116% and 88%, respectively, at baseline that did not change over a year of follow up. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All three subjects demonstrated significant
reductions in liver volume (17.1% +/- 1.9%), and spleen volume (17.6% +/- 7.1%) from baseline, as measured by MRI at 30 days post-injection.
</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Per the design of the clinical trial, subjects
in the low-dose cohort received a single, intravenous injection of AB0-102 to deliver the AAV viral vector systematically throughout
the body to introduce a corrective copy of the gene that underlies the cause of the MPS IIIA disease. Subjects were evaluated at
multiple time points over the initial 30 days post-injection for safety assessments and initial signals of biopotency, which suggest
that ABO-102 successfully reached target tissues throughout the body, including the central nervous system, to reduce GAG content
that underlies the lysosomal storage pathology central to Sanfilippo syndrome type A (MPSIIIA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We remain encouraged by continued
signs of tolerability and by early signals demonstrating reduced urinary and CSF GAG,&rdquo; stated Kevin M. Flanigan, MD, principal
investigator with the Center for Gene Therapy at Nationwide Children&rsquo;s Hospital and Professor of Pediatrics and Neurology
at The Ohio State University College of Medicine. &ldquo;Additionally, we are informed by the natural history study that subjects
with MPS IIIA experience hepatosplenomegaly, and are pleased by observations in the low dose cohort of significant reductions in
liver and spleen volumes 30 days post-injection as measured by MRI.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A more complete analysis of these data
will be presented from the low-dose cohort and initial high dose cohort at a scientific conference in the first quarter of 2017.
The Data Safety Monitoring Board has approved dose escalation of the high dose cohort this quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;The data demonstrate an early and
robust systemic delivery of ABO-102, and the reductions in CNS and urinary GAG support our approach for intravenous delivery of
ABO-102 for subjects with Sanfilippo syndromes,&rdquo; stated Timothy J. Miller, Ph.D, President and CEO of Abeona Therapeutics.
&ldquo;We are excited about early biomarker signals in this trial, including the reductions in liver and spleen volumes. Positive
impact on hepatosplenomegaly has been an important measure historically in other clinical programs in the lysosomal storage disease
space.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Abeona&rsquo;s MPS IIIA program, ABO-102,
has been granted Orphan Product Designation in the USA and received the Rare Pediatric Disease Designation, and recently announced
Orphan Drug Designation has been granted in the European Union.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Conference Call:</B> Management will
be hosting a conference call today at 4:30p EDT to update investors on ABO-102 recent developments and ongoing progress in additional
programs within the Company. Interested parties can access the call by dialing 877.269.7756.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About ABO-102 (AAV-SGSH):<I> </I></B>ABO-102
is an adeno-associated viral (AAV)-based gene therapy for subjects with MPS IIIA (Sanfilippo syndrome), that is delivered as a
one-time intravenous injection. ABO-102 delivers a functioning, corrective copy of the SGSH gene to cells of the central nervous
system (CNS) and other organs with the goal of correcting the underlying deficits caused by the inborn genetic errors that are
the cause the disease. ABO-102 has been well tolerated through 30-day post-injection in subjects injected with the low-dose (n=3).
The clinical study is supported by neurocognitive evaluations, biochemical assessments and MRI data generated in a 25-subject
MPS III natural history study, also conducted at Nationwide Children's Hospital, where subjects continued through one-year of
follow up assessments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sanfilippo syndromes</B> (or mucopolysaccharidosis
(MPS) type III): a group of four inherited genetic diseases each caused by a single gene defect, described as type A, B, C or D,
which cause enzyme deficiencies that result in the abnormal accumulation of glycosaminoglycans (GAGs, or sugars) in body tissues.
MPS III is a lysosomal storage disease, a group of rare inborn errors of metabolism resulting from deficiency in normal lysosomal
function. The incidence of MPS III (all four types combined) is estimated to be 1 in 70,000 births. Mucopolysaccharides are long
chains of sugar molecule used in the building of connective tissues in the body. There is a continuous process in the body of replacing
used materials and breaking them down for disposal. Children with MPS III are missing an enzyme which is essential in breaking
down the used mucopolysaccharides called heparan sulfate. The partially broken down mucopolysaccharides remain stored in cells
in the body causing progressive damage. In MPS III, the predominant symptoms occur due to accumulation within the central nervous
system (CNS), including the brain and spinal cord, resulting in cognitive decline, motor dysfunction, and eventual death. Importantly,
there is no cure for MPS III and treatments are largely supportive care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>About
Abeona:</B> Abeona Therapeutics Inc. is a clinical stage company developing gene and plasma-based therapies for life-threatening
rare genetic diseases. Abeona's lead programs are ABO-102 (AAV-SGSH) and ABO-101 (AAV-NAGLU), adeno-associated virus (AAV) based
gene therapies for Sanfilippo syndrome (MPS IIIA and IIIB), respectively. Abeona is also developing EB-101 (gene-corrected skin
grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL);
ABO-202 (AAV-CLN1) gene therapy for treatment of infantile Batten disease (INCL), and ABO-301 (AAV-FANCC) for Fanconi anemia (FA)
disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona has
a plasma-based protein therapy pipeline, including SDF Alpha&trade; (alpha-1 protease inhibitor) for inherited COPD, using our
proprietary SDF&trade; (Salt Diafiltration) ethanol-free process. For more information, visit </FONT>www.abeonatherapeutics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-style: normal; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><I>This
press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933,
as amended, and that involve risks and uncertainties. These statements include, without limitation, our plans for continued development
and internationalization of our clinical programs, that ABO-102 is well-tolerated, that studies will continue to enroll in the
US and internationally and that early signs of potency are encouraging and will continue These statements are subject to numerous
risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll subjects
in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or
obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other
risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company
with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking
statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release,
whether as a result of new information, future developments or otherwise.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Investor
Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Christine Silverstein</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vice President, Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Abeona Therapeutics Inc.<BR>
+1 (212)-786-6212</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">csilverstein@abeonatherapeutics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Contact:</B><BR>
Andre&rsquo;a Lucca<BR>
Vice President, Communications &amp; Operations<BR>
Abeona Therapeutics Inc.<BR>
+1 (212)-786-6208</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">alucca@abeonatherapeutics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>pg1img1_ex99-1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg1img1_ex99-1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ =@$G P$1  (1 0,1 ?_$ ,8  0 " @(# 0$
M       '" 8)! H" P4!"P$!  (" P$!              4&! <! @,("1
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M)DH RCM5XNG'J$= 5 $NVIWTIJYQ_P ?TL199&]/5=1<EH!2)"#N9*'U$-0
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MVX=\)#OZBJ"=DAIMD<#]W;50QX*:\MVM5?-UAEYXK2]A#/AH@^\+4A)"11W
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M;!PIC6;*TY \D6,C6(,S5<B3^EXU6 T;<[N+@52%C7CPK@(J,6/L .'"JY1
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M(_37:1;MT&B"#5J@BV:MD4V[9LW3(B@W01(5-%!!%,I4TD4DR@4I2@!2E
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M.]P"J)2CLU0W"AIP!)) '/5Z[\G[=M^W)'[G5WQF]/0A(9WK5%6A7C45XD
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MQJ!XC6A.T<+_ ,1\_=]W=QQ;\0"8X8FJ :?:.!!I&IXT^Z1B? ZWA?\ 1/\
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MI5M-9+70HKD(PPHO..+\I? 9P5P*VE"O$$TX=PR$R&R@#W-D["O;F ;(6^$
MNO>7&/6?J[TVI(;<S[1'TZLE10U<-QX<N-?/<&<%A/F2;;VD%^T/2V/N:,7
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M^S4Q],PZ2CO,%TK\XY2>_P!P:ZPC[/,(18HEE#('*FW,@B+=04>M27@AQ/\
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M&1FE>,%F*OM4*C,0%))(%0*Z[OFKZ[7%Q6(CBFR$)E9G!<(JQ*Y"J&3<Q+J
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M^SMVECQ][;+.02K2(M)#(@;:H8_RFV$J.8W T->I[@O[?"7UW.L3WUG<M""
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M9,R>IQ7',)L8.DLS!@5;(O\ 9PY'WFQR8E0%+$7'()@ R?=6M! C2EV\Q]8
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AW([?.+MC*7&'%NVS;U=AAZ#;M^T?;TJD=2AW4IZZ:__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
